Mechanism of Modified Erzhiwan Combined with Epimedium for Atherosclerosis Based on Network Pharmacology

Xiao-qiang OU-YANG; Lian RAO; Min LEI; Xiao-kun CHEN; Chuang-xiong HONG

doi:10.13422/j.cnki.syfjx.20200336

您当前的位置：

首页 >

文章列表页 >

Mechanism of Modified Erzhiwan Combined with Epimedium for Atherosclerosis Based on Network Pharmacology

Data Mining | 更新时间：2021-02-09

- Mechanism of Modified Erzhiwan Combined with Epimedium for Atherosclerosis Based on Network Pharmacology
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 3, Pages: 175-182(2020)
- 作者机构：
  
  1.广州中医药大学　第一临床医学院，广州　 510405
  2.广州中医药大学　第一附属医院，广州　 510405
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20200336
  CLC： R22; R24; R289; G353.11
- Published：05 February 2020，
  
  Published Online：21 October 2019，
  
  Received：16 July 2019，
- 稿件说明：
扫描看全文
Xiao-qiang OU-YANG, Lian RAO, Min LEI, et al. Mechanism of Modified Erzhiwan Combined with Epimedium for Atherosclerosis Based on Network Pharmacology. [J]. Chinese Journal of Experimental Traditional Medical Formulae 26(3):175-182(2020)
DOI：

Xiao-qiang OU-YANG, Lian RAO, Min LEI, et al. Mechanism of Modified Erzhiwan Combined with Epimedium for Atherosclerosis Based on Network Pharmacology. [J]. Chinese Journal of Experimental Traditional Medical Formulae 26(3):175-182(2020) DOI： 10.13422/j.cnki.syfjx.20200336.

摘要

目的：

运用网络药理学研究方法探讨加味二至丸治疗更年期女性动脉粥样硬化的作用机制。

方法：

在中药系统药理学分析平台(TCMSP)和中药分子机制的生物信息学分析工(BATMAN-TCM)筛选加味二至丸的成分和靶点；并通过相关数据库检索动脉粥样硬化相关靶点；通过韦恩图得到加味二至丸和动脉粥样硬化的共同靶点，利用Cytoscape 3.6.1建立成分-疾病-靶点作用网络，然后使用STRING网站进行化合物-疾病共同靶点蛋白互作分析、运用Cytoscape 3.6.1进行可视化，并使用复合分子检测法(MCODE)分析重要模块；利用David数据库进行基因本体(GO)分析和京都基因与基因组百科全书(KEGG)通路富集分析。

结果：

筛选出加味二至丸38个成分和266个预测靶点，动脉粥样硬化靶点254个；通过韦恩图得到共同靶点52个，筛选出14个关键基因；这些共同靶点涉及炎症反应、调节胰岛素分泌、一氧化氮的合成调节等生物学过程；生物学通路包括肿瘤坏死因子信号通路、核转录因子-

B(NF-

B)信号通路、过氧化物酶体增殖物激活受体信号通路等22条信号通路。

结论：

加味二至丸可能通过雌激素受体调节雌激素水平，并可能通过抑制炎症反应，改善胰岛素抵抗等机制治疗动脉粥样硬化。

Abstract

Objective:

In this study

a network pharmacology-based method was applied to analyze the mechanism of modified Erzhiwan combined with epimedium in treatment of atherosclerosis.

Method:

The compounds and targets of modified Erzhiwan combined with epimedium were screened in traditional Chinese medicine(TCM) systems pharmacology database and analysis platform (TCMSP) and bioinformatics analysis tool for molecular mechanism of TCM (BATMAN-TCM). Mang related databases were applied to find the target-related to atherosclerosis.The common targets of modified Erzhiwan combined with epimedium and atherosclerosis were got by venn diagrams.Cytoscape 3.6.1 was used to construct ingredients-disease-targets networks.Then protein-protein interaction (PPI) analysis of ingredients-disease-targets was builed in STRING database

and was visualized by Cytoscape 3.6.1

then important modules were analyzed with Moleculaar complex detection(MCODE). Biological information annotation databases (DAVID) was used to carry on gene ontology (GO) analysis and enrichment analysis of gene encyclopedia kyoto encyclopedia of genes and genomes (KEGG) pathway.

Result:

A total of 38 active ingredients and 266 potential targets of modified Erzhiwan combined with epimedium were obtained from TCMSP and BATMAN-TCM

254 atherosclerosis-related targets were retrieved from disease database.Then 52 common targets were obtained and 14 core genes were screened.Biological processes were related to inflammatory response

regulation of insulin secretion

positive regulation of nitric oxide biosynthetic process

etc.The biological pathways mainly included tumor necrosis factor signaling pathway

NF-kappa B(NF-

B)signaling pathway

peroxisome proliferators-activated receptors signaling pathway and so on.

Conclusion:

Modified Erzhiwan combined with epimedium may play the anti-atherosclerosis role by estrogen-like effect through attach estrogen receptor

inhibiting inflammation and improving insulin resistance

which may provide guidance for further experimental research.

关键词

网络药理学加味二至丸动脉粥样硬化机制

Keywords

network pharmacologymodified Erzhiwanatherosclerosismechanism

references

P Joseph，D Leong，M Mckee, et al.Reducing the global burden of cardiovascular disease，part 1: the epidemiology and risk factors[J]．Circ Res，2017，121(6)：677-694.

张航向，宁晓暄，王晓明．女性心血管疾病的研究进展[J]．中华老年心脑血管病杂志，2015，17(1)：95-97.

T C Register，S E Appt，T B Clarkson．Atherosclerosis and vascular biologic responses to estrogens: histologic，immunohistochemical，biochemical，and molecular methods[J]．Methods Mol Biol，2016，1366：517-532.

A Iorga，C M Cunningham，S Moazeni，et al.The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy[J]．Biol Sex Differ, 2017，8(1)：33.

刘超，王阶．从补肾对血脉的影响探讨其在冠心病治疗中的应用与研究[J]．中华中医药杂志，2018，33(3)：841-843.

魏晓娜．加味二至丸对高血压绝经后患者胰岛素抵抗影响的研究[D]．广州：广州中医药大学，2016.

张和针．加味二至丸对绝经后女性高血压患者雌激素、血脂、内皮功能影响的临床研究[D]．广州：广州中医药大学，2015.

徐进文，许洁安，李润美，等．加味二至丸对卵巢切除小鼠的影响[J]．广州中医药大学学报，2013，30(3)：367-371.

师帅，胡元会，吴华芹，等．“丹参-三七”药对作用机制的网络药理学探讨[J]．中国实验方剂学杂志，2018，24(18)：192-197.

汤化琪，梁瑞敏，陈宇，等．BATMAN-TCM在线分析工具预测玄胡索散治疗骨关节炎作用及初步验证研究[J]．中华中医药学刊，2018，36(1)：142-145.

黄秀芳，高运吉，廖钢，等．基于网络药理学探索射麻止喘液治疗哮喘的作用机制[J]．中国实验方剂学杂志，2019，doi：10.13422/j.cnki.syfjx.20191461http://dx.doi.org/10.13422/j.cnki.syfjx.20191461.

蔡秀江，黄美艳，丁安伟，等．二至丸考源及药理作用研究进展[J]．中国实验方剂学杂志，2011，17(23)：272-275.

朱瑞清，李志忠，周建，等．淫羊藿苷及其拟代谢物的雌激素样作用研究[J]．中医药学报，2012，40(3)：15-20.

胡彦武，刘凯，闫梦彤，等．淫羊藿总黄酮及淫羊藿苷的心血管保护作用及机制研究进展[J]．中国实验方剂学杂志，2015，21(13)：227-230.

A Basu, A S Das, M Majumder, et al.Antiatherogenic roles of dietary flavonoids chrysin，quercetin，and lluteolin[J]．J Cardiovasc Pharmacol，2016，68(1)：89-96.

R V Patel，B M Mistry, S K Shinde，et al.Therapeutic potential of quercetin as a cardiovascular agent[J]．Eur J Med Chem，2018，155：889-904.

Z JIA，P Nallasamy, D LIU, et al.Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IKappaBalpha/NF-kappaB signaling pathway[J]．J Nutr Biochem, 2015，26(3)：293-302.

D JIANG, D LI, W WU．Inhibitory effects and mechanisms of luteolin on proliferation and migration of vascular smooth muscle cells[J]．Nutrients, 2013，5(5)：1648-1659.

Y T WU, L CHEN, Z B TAN, et al.Luteolin inhibits vascular smooth muscle cell proliferation and migration by inhibiting TGFBR1 signaling[J]．Front Pharmacol, 2018，9：1059.

F XIA, C WANG, Y JIN, et al.Luteolin protects HUVECs from TNF-alpha-induced oxidative stress and inflammation via its effects on the Nox4/ROS-NF-kappaB and MAPK pathways[J]．J Atheroscler Thromb, 2014，21(8)：768-783.

丁淑敏，宋国强，张烨，等．去甲基蟛蜞菊内酯对香烟烟雾干预NHBE细胞损伤的保护作用[J]．常州大学学报：自然科学版，2017，29(4)：32-38.

E Kassi, E Spilioti, N Nasiri-Ansari, et al.Vascular inflammation and atherosclerosis：the role of estrogen receptors[J]．Curr Med Chem，2015，22(22)：2651-2665.

G Pare，A Krust，R H Karas, et al.Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury[J]．Circ Res，2002，90(10)：1087-1092.

郑红霞，赵元，徐颖，等．二至丸对未成熟小鼠雌激素样作用分析[J]．中国实验方剂学杂志，2018，24(4)：103-107.

李晓曦，陈宇恒，唐秀凤，等．基于雌激素作用的淫羊藿女贞子配伍对绝经后骨质疏松症大鼠的影响研究[J]．中国中医骨伤科杂志，2019，27(9)：1-6.

R O Escarcega, M J Lipinski, M Garcia-Carrasco，et al.Inflammation and atherosclerosis: cardiovascular evaluation in patients with autoimmune diseases[J]．Autoimmun Rev，2018，17(7)：703-708.

S J Bielinski, J S Pankow, N LI, et al.ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA)[J]．Atherosclerosis，2008，201(2)：339-344.

I Voloshyna，M J Littlefield，A B Reiss．Atherosclerosis and interferon-gamma：new insights and therapeutic targets[J]．Trends Cardiovasc Med，2014，24(1)：45-51.

聂映，姚卫峰．二至丸不同极性部位对抗大鼠酒精性肝损伤的作用及机制[J]．中国实验方剂学杂志，2014，20(20)：145-149.

X H YU, X L ZHENG, C K TANG．Nuclear factor-kappaB activation as a pathological mechanism of lipid metabolism and atherosclerosis[J]．Adv Clin Chem, 2015，70：1-30.

Y K Kim, J S Shin, M H Nahm．NOD-like receptors in infection, immunity, and diseases[J]．Yonsei Med J, 2016，57(1)：5-14.

S Kanno, H Nishio, T Tanaka, et al.Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/-mice[J]．J Immunol, 2015，194(2)：773-780.

P XU, Y ZHAI, J WANG．The role of PPAR and its cross-talk with CAR and LXR in obesity and atherosclerosis[J]．Int J Mol Sci，2018，19(4)：1260-1277.

E A Ivanova, V A Myasoedova, A A Melnichenko, et al.Peroxisome proliferator-activated receptor (PPAR) gamma wgonists as therapeutic agents for cardiovascular disorders：focus on atherosclerosis[J]．Curr Pharm Des, 2017，23(7)：1119-1124.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Explore Potential Molecular Mechanism of Gegen Qinliantang in Intervention of Atherosclerosis Based on Network Pharmacology and Molecular Docking

Pharmacological Effect of Glycyrrizae Radix et Rhizoma Compatibility and Its Mechanism

Mechanism of Polygonati Rhizoma on Treating Osteoporosis Based on Network Pharmacology and Preliminary Verification

Mechanism of Gegen Qinliantang against Vulnerable Plaque of Atherosclerosis： Based on Macrophage Pyroptosis Mediated by NF-κB/NLRP3/Caspase-1 Pathway

Gegen Qinliantang Regulates Polarization Tendency of Macrophages to Intervene in Vulnerable Plaque in AS of ApoE^-/- Mice

Related Author

Yi ZHENG

He GUO

Xi LUO

Yan-jie WANG

Dan-yu ZHAO

Xiao-fan FENG

Bao-kun LI

Jing-yu WANG

Related Institution

Liaoning University of Traditional Chinese Medicine，Shneyang

ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research，Guangxi University of Chinese Medicine

Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica， Guangxi University of Chinese Medicine

Wangjing Hospital，China Academy of Chinese Medical Sciences

Beijing Longfu Hospital

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰